SCHEDULE 13G/A 0001193125-24-036348 0001611024 XXXXXXXX LIVE 2 Common Stock 12/31/2024 0001737287 Allogene Therapeutics, Inc. 019770106 210 East Grand Avenue South San Francisco CA 94080 Rule 13d-1(d) David D. Chang, M.D., Ph.D. X1 7991807.00 2913196.00 7991807.00 2913196.00 10905003.00 5.1 IN Chang 2006 Family Trust CA 0.00 1201108.00 0.00 1201108.00 1201108.00 0.6 OO JEC 2019 Trust CA 0.00 856044.00 0.00 856044.00 856044.00 0.4 OO RTC 2019 Trust CA 856044.00 856044.00 856044.00 0.4 OO Allogene Therapeutics, Inc. 210 East Grand Avenue, South San Francisco, CA, 94080. David D. Chang, M.D., Ph.D. Chang 2006 Family Trust JEC 2019 Trust RTC 2019 Trust David D. Chang, M.D., Ph.D.: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 Chang 2006 Family Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 JEC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 RTC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 David D. Chang, M.D. Ph.D.: USA Chang 2006 Family Trust: California JEC 2019 Trust: California RTC 2019 Trust: California Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Chang's cover page includes 5,226,158 shares of common stock issuable within 60 days of December 31, 2024 upon the exercise of stock options held by Dr. Chang and 105,934 shares issuable upon the settlement of Restricted Stock Units held by Dr. Chang that are releasable within 60 days of December 31, 2024, and also includes (a) 1,201,108 shares of common stock beneficially owned by the Chang 2006 Family Trust, of which Dr. Chang is co-trustee, (b) 856,044 shares of common stock beneficially owned by the JEC 2019 Trust, of which Dr. Chang is co-trustee and (c) 856,044 shares of common stock beneficially owned by the RTC 2019 Trust, of which Dr. Chang is co-trustee. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 209,672,091 shares of common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2024. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Y Y Y Y Y Y Joint Filing Agreement David D. Chang, M.D., Ph.D. /s/ David D. Chang 02/13/2025 Chang 2006 Family Trust /s/ David D. Chang 02/13/2025 JEC 2019 Trust /s/ David D. Chang 02/13/2025 RTC 2019 Trust /s/ David D. Chang 02/13/2025